Eculizumab in a Patient with Dense-Deposit Disease
- 22 March 2012
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 366 (12), 1161-1163
- https://doi.org/10.1056/nejmc1112273
Abstract
In 1999, an 11-year-old girl with the nephrotic syndrome received a biopsy-confirmed diagnosis of membranoproliferative glomerulonephritis. The level of plasma complement C3 was 7 mg per deciliter (normal range, 90 to 180). Glucocorticoids, administered for 5 years, were ineffective.Keywords
This publication has 5 references indexed in Scilit:
- Dense deposit diseaseMolecular Immunology, 2011
- New Approaches to the Treatment of Dense Deposit DiseaseJournal of the American Society of Nephrology, 2007
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaThe New England Journal of Medicine, 2006
- Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient miceProceedings of the National Academy of Sciences of the United States of America, 2006
- Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease)Journal of the American Society of Nephrology, 2005